期刊
VIRUSES-BASEL
卷 13, 期 6, 页码 -出版社
MDPI
DOI: 10.3390/v13061082
关键词
coxsackievirus B; oncolytic virus; cancer; virotherapy; cancer; toxicity; anti-tumor immunity
类别
资金
- Canadian Cancer Research Society
- British Columbia Lung Association
- Providence Health Care Research Institute and Vancouver Coastal Health Research Institute Innovation and Translational Research Award
- MITACS Accelerate program
Oncolytic viruses, particularly coxsackievirus group B (CVBs), have shown promising potential in cancer therapy by selectively infecting and destroying tumor cells, as well as inducing systemic anti-tumor immunity. Type 3 CVBs have demonstrated potent anti-tumor activities against various cancer types. Strategies to enhance specificity and safety of CVBs towards tumor cells are being explored to further increase their anti-tumor efficacy.
Oncolytic viruses have emerged as a promising strategy for cancer therapy due to their dual ability to selectively infect and lyse tumor cells and to induce systemic anti-tumor immunity. Among various candidate viruses, coxsackievirus group B (CVBs) have attracted increasing attention in recent years. CVBs are a group of small, non-enveloped, single-stranded, positive-sense RNA viruses, belonging to species human Enterovirus B in the genus Enterovirus of the family Picornaviridae. Preclinical studies have demonstrated potent anti-tumor activities for CVBs, particularly type 3, against multiple cancer types, including lung, breast, and colorectal cancer. Various approaches have been proposed or applied to enhance the safety and specificity of CVBs towards tumor cells and to further increase their anti-tumor efficacy. This review summarizes current knowledge and strategies for developing CVBs as oncolytic viruses for cancer virotherapy. The challenges arising from these studies and future prospects are also discussed in this review.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据